StemCellsChina.com
Fill out my online form.
Autres Nouvelles
| Omega-3 Fatty Acids May Slow Very Early Alzheimer's |
 |
 |
| International News | |||
| Mercredi, 11 Octobre 2006 17:52 | |||
|
There are no translations available. Source: Archives of Neurology NEW YORK (Reuters Health) - Dietary supplementation with omega-3 fatty acids for 6 months appears to be of little benefit in patients with mild to moderateAlzheimer's disease (AD), according to results of a study conducted in Sweden.However, a second look at the data suggests that omego-3 fatty acids may protect cognitive function in patients with very mild, early stage AD.Studies have shown that a diet rich in omega-3 fatty acids, as found in fish oil, reduces the risk of AD. Furthermore, animal studies have shown that the two predominant omega-3 fatty acids in fish oil, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), preserve cognitive function.To evaluate the effect of DHA/EPA on patients already diagnosed with AD, investigators led by Dr. Jan Palmblad, from Karolinska University Hospital Huddinge in Stockholm, randomly recruited 174 patients with mild to moderate AD. Eighty-nine patients were assigned 430 mg DHA plus 150 mg EPA, administered four times daily, and 85 were assigned placebo for 6 months during blinded portion of the trial. For the next 6 months, both groups were given the DHA/EPA supplement. As demonstrated by Mini-Mental State Examination (MMSE) scores and the modified cognitive portion of the Alzheimer Disease Assessment Scale (ADAS-COG), the two treatment groups did not differ significantly at 6 months or at 12 months. But when Palmblad's group conducted a post-hoc analysis of the 32 patients with very mild AD at baseline, those first treated with placebo exhibited a significant decline in MMSE score at 6 months, whereas scores remained stable in those treated with DHA/EPA. The researchers say their results, coupled with other studies, "support the idea that omega-3 fatty acids have a role in primary prevention of AD but not in treatment of manifest disease," when the "neuropathologic involvement is too advanced to be substantially attenuated by anti-inflammatory treatment."
|
|||
| Mise à jour le Jeudi, 19 Octobre 2006 17:53 |